Therefore, FGFR1 overexpression appears to occur independently of gene amplification in lung cancer and potentially other cancer types, supporting the future inclusion of FGFR mRNA and protein levels in fusion-negative cases as potential screening biomarkers into clinical trial design of FGFR-targeted therapy. The gene discussed is FGFR1; the disease is cancer.